跳转至内容
Merck
CN
  • Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Increased cardiovascular risk in patients with rheumatoid arthritis: an overview.

Acta cardiologica (2014-05-03)
Daisy Puttevils, Philip De Vusser, Piet Geusens, Jo Dens
摘要

Patients with established rheumatoid arthritis (RA) have a higher cardiovascular morbidity and mortality in comparison with the general population. It is considered to be an independent risk factor for cardiovascular disease. The purpose of this article is to describe the mechanisms responsible for accelerated atherogenesis in RA patients and to give an overview of the effects of different RA therapies (methotrexate, TNF antagonists and other biologicals).

材料
Product Number
品牌
产品描述

Sigma-Aldrich
甲氨蝶呤 水合物, ≥98% (HPLC), powder
Sigma-Aldrich
甲氨蝶呤 水合物, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
甲氨蝶呤, meets USP testing specifications
SAFC
甲氨蝶呤
Supelco
甲氨蝶呤, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
甲氨蝶呤,1 X 100MG 溶液, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
甲氨蝶呤, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
甲氨蝶呤 水合物, ≥99.0% (sum of enantiomers, HPLC)
甲氨蝶呤, European Pharmacopoeia (EP) Reference Standard
甲氨蝶呤, European Pharmacopoeia (EP) Reference Standard